PLERIXAFOR INJECTION DIN 02529815
Health Canada record
| Active ingredient(s) | PLERIXAFOR 20 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L03AX16 PLERIXAFOR |
| Original market date | 31-Aug-2023 |
| Current status date | 31-Aug-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PLERIXAFOR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02490846 | PLERIXAFOR INJECTION | FRESENIUS KABI CANADA LTD | Solution | PLERIXAFOR 20 MG | Approved |
| 02539454 | PLERIXAFOR INJECTION | EUGIA PHARMA INC. | Solution | PLERIXAFOR 20 MG | Marketed |
| 02377225 | MOZOBIL | SANOFI-AVENTIS CANADA INC | Solution | PLERIXAFOR 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28790 | 2022-08-19 | Abbreviated New Drug Submission (ANDS) |
International API supply for PLERIXAFOR
8 active FDA Drug Master Files.
Request a quote for PLERIXAFOR INJECTION